CA-ENCHROMA
EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/
In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering they’re color blind.
A contributing factor is the lack of testing for color blindness in schools. According to EnChroma, only 11 of 50 states test for CVD. As a result, many students do not realize they’re color blind. In fact, nearly half of color blind people said they didn’t learn they’re color blind until after 7th grade, almost one in three while in high school or later, and one in five don’t find out until after high school or college.
“The evidence is overwhelming that color blindness creates learning challenges for color blind students and that parents, educators, and politicians must become more aware of the prevalence of color vision deficiency, and its impact, and take action,” said Erik Ritchie, CEO of EnChroma. “Too many kids go deep into their educations without the student, their parents or teachers knowing they’re color blind. Testing for color blindness has to become universal in schools in all states and countries, and learning materials adapted to accommodate and create a level playing field for CVD students.”
One in 12 men (8%) and one in 200 women (.5%) are color blind – 13 million in the US, 30 million in Europe, and 350 million worldwide. For them, understanding colorful information in school, at work and in daily life can cause obstacles. While people with normal color vision see over one million shades of color, the color blind only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red and brown, with colors appearing muted and dull. Since 80% of information is conveyed visually, this creates issues for color blind students.
Numerous renowned universities plan to offer EnChroma glasses to color blind students to borrow on their campuses, and to educate staff to adapt materials to accommodate CVD students. They include Boston University, North Carolina State University, Alfred University and Francis Marion University, with others joining soon.
Click here for more images of how the color blind see colors.
“A teacher discovered I was color blind in the third grade. Up to that point I was often referred to as “stupid” because I couldn’t color primary colors correctly,” said one color blind survey respondent. Another relayed: “I was unable to pass chromatography lessons in organic chemistry because I couldn't distinguish the colors accurately. I had to drop the class and eventually change majors.”
Highlights from the EnChroma survey include:
- Four out of ten color blind students try to avoid schoolwork and activities involving color, and nearly half are less interested in painting, drawing, nature walks and field trips to art museums
- More than 1 in three color blind people say teachers got frustrated with them when they couldn’t understand schoolwork involving color
- Only one in four parents tell teachers that their child is color blind, and only 20% of teachers adapt schoolwork to accommodate color vision deficient students
- 81% believe teachers should adapt teaching materials for color blind students
- 87% support mandatory testing of schoolchildren for color vision deficiency
- One in four were teased by classmates or teachers due to being color blind
- Two of three parents worry about color blindness affecting their child’s education
EnChroma encourages schools to quickly and easily test students in under two minutes for color blindness via our free online test available here and at enchroma.com . To read comments from color blind respondents about their educational experiences click here .
EnChroma Color Accessibility Program
EnChroma is the lead advocate for “color accessibility” through its EnChroma Color Accessibility Program . The program helps public venues, schools, state parks, libraries, museums, and other organizations purchase and loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the CVD. In addition to our free color blindness test, EnChroma also offers materials for schools to share with teachers, parents and students to educate them about color blindness, its effects, and how to support color blind students. EnChroma offers a similar program for employers.
EnChroma glasses are engineered with special optical filters that help the color blind see an expanded range of colors more vibrantly, clearly and distinctly. A recent study by the University of California, Davis, and France’s INSERM Stem Cell and Brain Research Institute , demonstrated the effectiveness of EnChroma glasses.
Media: Product shots, images and interactive GIFs illustrating the challenges to learning for those with color vision deficiencies can be downloaded here. EnChroma’s CEO, survey respondents, and university and K-12 educators and parents, are available for interviews. Of the nearly 1,000 respondents to the survey, nearly three-fourths are color blind (740) and the other 247 the parents of color blind children.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance . For more information call 510-497-0048 or visit enchroma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005173/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
